Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teva settles patent litigation with Amarin; gets rights to market generic Vascepa in US

Executive Summary

Teva Pharmaceutical Industries Ltd. and Amarin Corp. PLC have settled patent litigation surrounding Teva's ANDA for generic Vascepa (icosapent ethyl) capsules. Under the settlement, Teva can market icosapent ethyl in the US beginning on August 9, 2029. Vascepa is a single molecule product consisting of the omega-3 acid known as EPA in ethyl-ester form and is proven to lower triglyceride levels without raising LDL-cholesterol levels. Ongoing patent litigation continues with West-Ward Pharmaceuticals Corp and Dr. Reddy's Laboratories Inc.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register